Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 13/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.63 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KIF23 | Q02241 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644013 | 0.93 | KIF11 (0.75) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL645968 | 0.91 | KIF11 (0.60) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL645675 | 0.86 | KIF11 (0.71) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL644014 | 0.86 | KIF11 (0.73) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL646430 | 0.86 | KIF11 (0.83) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL644051 | 0.86 | KIF11 (0.70) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL646386 | 0.84 | KIF11 (0.70) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL644773 | 0.84 | KIF11 (0.65) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL644258 | 0.83 | KIF11 (0.68) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL645538 | 0.83 | KIF11 (0.64) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119678-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110230550-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2011-09-22 | — | — | US | disclosed |
| US-7919524-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230550-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | KIF11 824/4885KCNH2 2582/4885MAP1LC3B 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.